The task force reviewed the available data on fatality rates of patients with cancer who developed COVID-19 and based their recommendation on 28 publications; their position paper was published in the AACR journal Cancer Discovery.
SOURCE: https://bit.ly/2Jce4ao Cancer Discovery, online December 19, 2020.
By Reuters Staff
Posted on
Previous Article
« Delaying cancer treatment during pandemic likely unnecessary Next Article
Jaw necrosis risk in cancer patients on zoledronic acid varies with dosing, oral health »
« Delaying cancer treatment during pandemic likely unnecessary Next Article
Jaw necrosis risk in cancer patients on zoledronic acid varies with dosing, oral health »
Related Articles
February 9, 2021
Anti-CD20 therapy for lymphoma tied to worse COVID-19 outcomes
July 18, 2022
Nebulised aviptadil “futile” in I-SPY COVID-19 trial
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
